CAL
OVID icon

Capital Advisors Ltd’s Ovid Therapeutics OVID Stock Holding History

Capital Advisors Ltd’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,710
Closed -$2K – 1523
2024
Q4 		$2K Buy
+1,710
New +$1.91K ﹤0.01% 1101

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capital Advisors Ltd's OVID Position: Q1 2025 in Review

Capital Advisors Ltd sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 1,710 shares — an estimated $2K sold.

Capital Advisors Ltd first reported a position in OVID in Q4 2024 and held it in 1 quarter. The position peaked at $2K in Q4 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • Capital Advisors Ltd reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 1,710 Ovid Therapeutics shares in Q1 2025, an estimated $2K.
  • Capital Advisors Ltd first reported a position in Ovid Therapeutics in Q4 2024 and held it in 1 quarter.
  • Capital Advisors Ltd's Ovid Therapeutics position peaked at $2K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on Capital Advisors Ltd's 13F filing for Q1 2025, filed 15 Apr 2025.